Sermorelin is not a testosterone treatment and has not been proven to directly raise testosterone. It acts on the growth hormone pathway by stimulating pituitary growth hormone release, which can increase IGF-1. Testosterone is regulated mainly through a separate reproductive hormone pathway, so low testosterone should be evaluated with labs and a clinician 1.
Wondering if sermorelin is right for you? Take the 3-min clinical quiz.
See if you qualify →Does sermorelin increase testosterone?
Sermorelin does not directly increase testosterone. The short answer is not directly: sermorelin acts on the hypothalamic-pituitary-somatotropic axis, which controls growth hormone and IGF-1, while testosterone is controlled through a different reproductive hormone pathway 1.
The short answer: not directly
Sermorelin is a synthetic version of the first 29 amino acids of growth hormone-releasing hormone, often written as GHRH(1-29). It signals the pituitary gland to release the body’s own human growth hormone, also called somatotropin, rather than supplying testosterone or human growth hormone directly 2.
Testosterone is an androgen made mainly by Leydig cells in the testes. That process is guided by gonadotropin-releasing hormone, luteinizing hormone, and follicle-stimulating hormone, not by sermorelin’s main target pathway 1.
Why growth hormone and testosterone symptoms can overlap
People often connect sermorelin with testosterone because symptoms can look similar. Fatigue, lower libido, erectile dysfunction, body-composition changes, poor recovery, and sleep problems can show up with low testosterone, lower growth hormone signaling, sleep apnea, thyroid disease, depression, medication effects, or metabolic conditions 1.
What evidence can and cannot show about testosterone changes
A review of growth hormone secretagogues in men described sermorelin and related compounds as GH and IGF-1 stimulators, but it also noted that clinical efficacy data in hypogonadal men remain limited 1. That means it is not accurate to present sermorelin as a proven low-testosterone treatment.
How does sermorelin work in the body?
Sermorelin acetate works like a signal, not a replacement hormone. In simple terms, it asks the pituitary gland to release growth hormone in a more body-led way, and clinicians may follow IGF-1 as one marker of growth hormone activity 2.
Sermorelin as a GHRH analog
Sermorelin is a growth hormone-releasing hormone analog and growth hormone secretagogue. “Secretagogue” means it stimulates a gland to release a hormone; in this case, the target is pituitary growth hormone release 1.
Pituitary growth hormone release and IGF-1
After growth hormone is released, the liver and other tissues produce insulin-like growth factor 1, or IGF-1. IGF-1 is often used in clinical care and research as a practical blood marker of growth hormone pathway activity 2.
How this differs from taking growth hormone directly
Recombinant human growth hormone supplies growth hormone directly. Sermorelin instead stimulates pituitary release, and older review literature argued this may preserve more normal feedback through hypothalamus, pituitary, somatostatin, growth hormone, and IGF-1 signals, though long-term outcome data remain limited 2.
Why do people connect sermorelin with testosterone?
Sermorelin and testosterone get compared because both sit inside the broader endocrine system. But an indirect symptom overlap is not the same as a proven testosterone increase 1.
Overlapping symptoms: fatigue, body composition, libido, and recovery
Low energy, lower libido, less lean body mass, more fat mass, and slower recovery are not specific to one hormone. They can occur with hypogonadism, poor sleep, untreated sleep apnea, diabetes, depression, medication side effects, under-eating, or overtraining 1.
Growth hormone, IGF-1, and the broader endocrine system
Hormone systems talk to each other, but they are not interchangeable. Growth hormone and IGF-1 can affect body composition and glucose metabolism, while testosterone affects androgen-sensitive tissues such as muscle, bone, sexual function, and red blood cell production 1, 5.
Why an indirect relationship is not the same as a proven testosterone increase
The key distinction is cause. Sermorelin may change GH and IGF-1 markers in some settings, but current evidence does not prove that sermorelin alone raises testosterone in men with low testosterone 1.
How is testosterone normally regulated?
Testosterone is mainly regulated through the hypothalamic-pituitary-gonadal axis. That axis uses 3 main signal steps: the brain sends GnRH, the pituitary sends LH and FSH, and the testes produce testosterone and sperm-related signals 1.
The hypothalamic-pituitary-gonadal axis
The hypothalamus releases gonadotropin-releasing hormone, or GnRH. GnRH tells the pituitary gland to release luteinizing hormone and follicle-stimulating hormone, often shortened to LH and FSH 1.
LH, FSH, Leydig cells, and testosterone production
LH signals Leydig cells in the testes to make testosterone. FSH helps support sperm production through related testicular cells, which is why a complete low-testosterone evaluation may include more than one hormone lab 1.
Why testosterone testing is different from IGF-1 testing
IGF-1 testing gives information about growth hormone pathway activity. Testosterone testing asks a different question: whether androgen levels are low enough, with symptoms, to support a diagnosis such as hypogonadism 1, 5.
Sermorelin vs testosterone therapy: what is the difference?
Sermorelin and testosterone therapy are not interchangeable. Sermorelin targets GH and IGF-1 signaling, while testosterone cypionate, testosterone enanthate, and testosterone undecanoate are forms of testosterone treatment used to raise androgen levels when clinically appropriate 5.
| Question | Sermorelin | Testosterone therapy |
|---|---|---|
| Main pathway | Growth hormone-releasing hormone pathway; pituitary GH release; IGF-1 | Hypothalamic-pituitary-gonadal axis and androgen replacement |
| Main hormone affected | Growth hormone activity and IGF-1 | Testosterone |
| Common labs clinicians may review | IGF-1, metabolic labs, safety history, symptom response | Morning total testosterone, sometimes free testosterone, LH, FSH, blood count, prostate-related monitoring when appropriate |
| What it is intended to affect | Growth hormone pathway activity; body-composition or wellness use may be off-label | Lab-confirmed testosterone deficiency when symptoms and clinical context fit |
| Evidence strength for raising testosterone | Not established as a direct testosterone-raising treatment | Directly raises testosterone in studied testosterone products |
| Monitoring focus | IGF-1 response, side effects, eligibility, glucose and risk factors | Testosterone level, hematocrit, symptoms, fertility goals, prostate and cardiovascular risk as clinically appropriate |
In testosterone trials, the active treatment is testosterone itself, not sermorelin. For example, randomized studies of testosterone reported dose-related effects on fat-free mass, muscle size, and strength, but those findings should not be attributed to sermorelin 3, 4.
If you want a plain-English overview of testosterone replacement, start with our guide to what TRT is. If your question is mainly about peptide differences, our article on CJC-1295 and ipamorelin vs sermorelin explains how growth-hormone secretagogues differ.
3-min quiz
Curious whether sermorelin fits your goals?
Chia offers sermorelin in injection, nasal spray, and tablet forms after an online health questionnaire and licensed US provider review. A prescription requires a medical evaluation and is not guaranteed. Compounded drugs, including compounded sermorelin, are not FDA-approved and have not been evaluated by FDA for safety, effectiveness, or quality as finished drug products.
What does the research say about sermorelin, testosterone, and body composition?
Human evidence supports a clear split: testosterone studies show direct androgen effects, while sermorelin research centers on GH and IGF-1. The honest answer is that sermorelin is not proven to raise testosterone, and individual results vary 1.
Human evidence for growth hormone and IGF-1 effects
Clinical trial records show that growth hormone-releasing hormone analogs have been studied in older adults and metabolic conditions. A terminated Phase 2 study planned 3 months of GHRH treatment in older adults, and a completed Phase 2 study tested a GHRH analog in nonalcoholic fatty liver disease and cardiovascular risk markers 8, 9.
Those trial registrations are useful for understanding what researchers have asked. They do not prove that sermorelin raises testosterone, improves libido, or changes body composition in every patient 8, 9.
Evidence limits for testosterone increases from sermorelin alone
A review of growth hormone secretagogues discussed possible roles for GH and IGF-1 stimulation in men with metabolic syndrome or hypogonadal symptoms, but it also stated that clinical efficacy data remain limited 1. That limitation matters when a symptom, like fatigue or libido change, could come from many causes.
What testosterone trials show about testosterone’s direct effects
In a randomized dose-response study, Bhasin and colleagues studied testosterone administration in healthy young men and reported dose-related changes in body composition and muscle measures 3. In another randomized trial, supraphysiologic testosterone doses increased muscle size and strength in normal men 4.
Those are testosterone findings, not sermorelin findings. More recent testosterone undecanoate research in men with hypogonadism has studied safety, efficacy, and pharmacokinetics for an oral testosterone product, again addressing testosterone replacement rather than growth hormone secretagogues 5.
Why muscle, weight, and libido claims need careful wording
Muscle, fat, and libido are multi-cause outcomes. Testosterone trials cannot be used to promise sermorelin outcomes, and compounded sermorelin has no FDA-evaluated outcomes data as a finished drug product 1, 5.
What are the downsides or risks of sermorelin?
Sermorelin side effects and eligibility questions should be reviewed before treatment. The main safety issue is not just the peptide itself; it is whether the person has risks such as active malignancy, diabetes, untreated sleep apnea, or medication interactions that change the risk-benefit picture 2.
Common side effects patients should know
Reported or clinically discussed effects with sermorelin and related growth hormone secretagogue use can include injection-site reactions, headache, flushing, dizziness, nausea, fluid retention, joint discomfort, or changes in glucose handling 1, 2. Our deeper guide to sermorelin side effects walks through what to ask a clinician before starting.
Who may need extra caution or may not be eligible
People with active malignancy, a history that raises concern for tumor growth, uncontrolled diabetes, significant fluid-retention risk, or untreated sleep apnea may need extra caution or may not be eligible. Growth hormone and IGF-1 pathways are involved in tissue growth and glucose metabolism, which is why clinician screening matters 2.
Why monitoring matters for compounded peptide therapy
Monitoring helps a clinician decide whether the treatment still makes sense. Depending on the person, follow-up may include symptom review, side-effect checks, IGF-1, metabolic labs, and changes in the care plan 1, 2.
Sports and performance-use considerations
Athletes in drug-tested sports should be careful with growth hormone secretagogues and hormone therapies. Rules vary by sport and testing body, so patients should check the policy that applies to them before using any performance-relevant prescription peptide or hormone.
How long do people stay on sermorelin?
Sermorelin duration is not one-size-fits-all. It depends on the reason for treatment, baseline labs, safety, side effects, response over follow-up visits, and whether the clinician still believes the benefits outweigh the risks 1.
Why duration depends on goals, labs, response, and safety
A person using sermorelin for a clinician-approved growth hormone pathway goal may be followed differently from a person being evaluated for low testosterone symptoms. Duration should be based on medical review, not a fixed internet timeline 1.
Follow-up monitoring rather than fixed timelines
Follow-up gives the clinician a chance to compare symptoms, side effects, IGF-1 trends, sleep, weight, glucose-related markers, and other health changes. If you are trying to understand prescription instructions, our sermorelin dosage chart explains how to read units and provider directions without turning them into self-dosing advice.
When a clinician may adjust or stop treatment
A clinician may adjust or stop sermorelin if side effects occur, labs move outside the intended range, a new risk appears, or the treatment is not helping the agreed goal. This is especially important for compounded peptide therapy because care should be individualized by a licensed provider.
Sermorelin at Chia: injections, nasal spray, or tablets after clinician review
At Chia, sermorelin is available only after an online health questionnaire and licensed US provider review. Plans currently start at $179/mo for sermorelin injection, and prescriptions are never guaranteed.
How Chia’s online evaluation works
You start with a short online health questionnaire. A licensed US provider reviews your health history, goals, medications, and safety factors, then prescribes only if treatment is clinically appropriate.
Available sermorelin forms at Chia
| Form at Chia | What to know | Current starting price |
|---|---|---|
| Injection | A provider-guided option for patients who are comfortable with injections and follow-up monitoring | From $179/mo |
| Nasal spray | A non-injection form that may fit patients who prefer not to inject | See the sermorelin product page |
| Tablets | An oral form option when a provider decides it fits the care plan | See the sermorelin product page |
Chia also offers a Foundation Longevity protocol that combines sermorelin injection with NAD+ injection and glutathione injection after clinician review. That protocol is separate from testosterone treatment and should not be viewed as a low-testosterone treatment.
What provider-guided dosing means
Provider-guided dosing means your prescriber chooses and adjusts treatment based on your history, goals, response, and safety. We do not recommend copying a dose from the internet or using “research chemical” peptides without a prescription.
Compounded 503A pharmacy fulfillment and at-home shipping
When prescribed through Chia, medications are compounded in the US by state-licensed 503A compounding pharmacies and shipped to your door. Patients can message their care team through the patient portal between visits.
When to use the eligibility quiz
The eligibility quiz is a good next step if you want a licensed provider to review whether sermorelin fits your health profile. If your main concern is low testosterone, a clinician may discuss testosterone labs, sleep, thyroid, weight, medications, or other causes instead.
What should you do if you suspect low testosterone?
Low testosterone should be evaluated with symptoms plus labs, not symptoms alone. A morning testosterone test is often central because testosterone varies across the day, and a clinician may need more than 1 data point depending on the situation 5.
Symptoms are not enough to diagnose low testosterone
Low libido, fatigue, erectile dysfunction, depressed mood, less muscle, and weight gain can point to low testosterone, but they are not diagnostic. Our guide to symptoms of low testosterone in men explains why lab confirmation matters.
Why morning testosterone labs matter
Testosterone levels can shift during the day and can be affected by sleep, illness, medications, energy deficit, and weight change. Testosterone studies and clinical evaluations rely on measured hormone levels rather than symptoms alone 5, 7.
When to ask about testosterone, thyroid, sleep, weight, medications, and other causes
A good evaluation looks beyond one hormone. Sleep apnea, thyroid disease, diabetes, depression, alcohol use, opioid use, some antidepressants, and severe calorie restriction can all affect energy, libido, weight, or testosterone-related symptoms 1, 7.
What to discuss with a licensed clinician
Ask what labs make sense, what risks apply to you, how fertility goals affect choices, and whether symptoms fit testosterone deficiency, growth hormone pathway concerns, or another cause. If testosterone therapy is being considered, risks and monitoring need careful review; randomized testosterone trials have found clinically important safety questions, including fracture outcomes in older men with hypogonadism 6.
FAQ
No. Sermorelin acts on the growth hormone pathway, not the testosterone pathway. It may affect growth hormone and IGF-1 activity, but it is not proven to directly raise testosterone.
It is not proven as a libido treatment. Libido can be affected by testosterone, sleep, stress, mood, medications, relationship factors, metabolic health, and other conditions. A clinician can help sort out the likely causes.
No peptide should be treated as a proven testosterone replacement. Some peptides are studied for reproductive hormone signaling, but low testosterone should be evaluated with labs and a licensed clinician. Testosterone therapy is the direct hormone-replacement approach when clinically appropriate.
Sermorelin is not a guaranteed muscle-building treatment. Growth hormone and IGF-1 pathways are linked to body composition, but human evidence for sermorelin-specific muscle gains is limited, and results vary.
Some clinicians may evaluate both pathways in the same patient, but the combination is not automatically appropriate. It requires lab review, symptom review, safety screening, and follow-up. Do not combine hormone treatments without a prescriber.
No. Human growth hormone, or HGH, supplies growth hormone directly. Sermorelin is a GHRH analog that signals the pituitary gland to release growth hormone.
No. Compounded sermorelin is not FDA-approved and has not been evaluated by FDA for safety, effectiveness, or quality as a finished drug product. It should be used only when prescribed by a licensed clinician.
There is no single timeline that applies to everyone. Clinicians usually look at the original goal, side effects, follow-up labs such as IGF-1 when appropriate, and whether the treatment remains worth continuing.
3-min quiz
Start with a clinician review
If you are interested in sermorelin, Chia’s online visit can help determine whether it is appropriate for you. A licensed US provider reviews your information and prescribes only when clinically appropriate; a prescription is not guaranteed. For low-testosterone symptoms, your provider may recommend lab evaluation or a different care path.
References
- 1.Kovac JR, Pan M, Arent S, Lipshultz LI. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal and eugonadal men. Translational Andrology and Urology. 2020.
- 2.Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clinical Interventions in Aging. 2009.
- 3.Bhasin S, Woodhouse L, Casaburi R, et al. Testosterone dose-response relationships in healthy young men. American Journal of Physiology-Endocrinology and Metabolism. 2001.
- 4.Bhasin S, Storer TW, Berman N, et al. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. The New England Journal of Medicine. 1996.
- 5.Miner M, Wang C, Kaminetsky J, et al. Safety, efficacy, and pharmacokinetics of oral testosterone undecanoate in males with hypogonadism. Andrology. 2025.
- 6.Snyder PJ, Bauer DC, Ellenberg SS, et al. Testosterone Treatment and Fractures in Men with Hypogonadism. The New England Journal of Medicine. 2024.
- 7.Mohr AE, Berryman CE, Harris MN, et al. Testosterone administration partially modulates gut microbiota responses to severe energy deficit. American Journal of Physiology-Endocrinology and Metabolism. 2026.
- 8.ClinicalTrials.gov. Three Month Treatment of Growth Hormone Releasing Hormone (GHRH) in the Elderly. NCT01410799. 2011.
- 9.ClinicalTrials.gov. Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk. NCT03375788. 2017.
- 10.ClinicalTrials.gov. VRS-317 in Adult Subjects With Growth Hormone Deficiency. NCT01359488. 2011.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if sermorelin is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
